Literature DB >> 26045835

Association between COX-2 polymorphisms and non-small cell lung cancer susceptibility.

Tiancheng Zhang1, Jing Li1, Tian Xia1, Nan Zhang2, Yaozhou Zhang3, Jian Zhao1.   

Abstract

AIM: To explore the association between COX-2 polymorphisms and non-small cell lung cancer (NSCLC) susceptibility.
METHODS: We collected fasting peripheral venous blood from 60 cases with NSCLC and 62 healthy controls through physical examinations, and applied PCR-RFLP to analyze COX-2 polymorphisms of two groups.
RESULTS: With respect to detecting COX-2 rs689466 and rs5275 polymorphisms, the distribution frequency of mutant genotype AA of COX-2 rs689466 in case group was higher than that in control group, which possessed significant difference between two groups (P<0.05). Carriers with AA genotype were 4.05 times at risk of NSCLC than those with GG genotype (P = 0.04, OR=4.05, 95% CI=1.14-14.43). The distribution of mutant genotype CC of COX-2 rs5275 was different between two groups, and carriers with genotype CC were at 5.70 times higher risk of NSCLC than those with genotype TT. After corrected by sex, gender, smoking and drinking factors, AA genotype of COX-2 rs689466 and CC genotype of COX-2 rs5275 still contributed to increased risk of NSCLC (OR=4.22, 95% CI=1.10-16.17, OR=6.95, 95% CI=1.27-38.11). After analyzed of linkage disequilibrium (LD) and haplotypes of alleles in two SNPs, the distribution frequency of A-C haplotype in case group was higher than that in control group, with significant difference between two groups (P<0.05). After corrected by sex, gender, smoking and drinking factors, statistical difference was still found in the total distribution of A-C haplotype between two groups (P=0.03, OR=6.11, 95% CI=1.16-32.2).
CONCLUSIONS: COX-2 rs689466 and rs5275 polymorphisms may be related to NSCLC susceptibility. And A-C haplotype might be a susceptibility haplotype for NSCLC.

Entities:  

Keywords:  COX-2; non-small cell lung cancer; polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26045835      PMCID: PMC4440144     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

Review 1.  COX-2: a target for prevention and treatment of esophageal cancer.

Authors:  Nasser Altorki
Journal:  J Surg Res       Date:  2004-03       Impact factor: 2.192

2.  Lack of association between polymorphisms in inflammatory genes and lung cancer risk.

Authors:  Daniele Campa; Rayjean J Hung; Dana Mates; David Zaridze; Neonila Szeszenia-Dabrowska; Peter Rudnai; Jolanta Lissowska; Eleonóra Fabiánová; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Paul Brennan; Federico Canzian
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

3.  Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.

Authors:  R J Coffey; C J Hawkey; L Damstrup; R Graves-Deal; V C Daniel; P J Dempsey; R Chinery; S C Kirkland; R N DuBois; T L Jetton; J D Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

4.  Posttranscriptional Regulation of Cyclooxygenase 2 Expression in Colorectal Cancer.

Authors:  Lisa E Young; Dan A Dixon
Journal:  Curr Colorectal Cancer Rep       Date:  2010-04

5.  Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.

Authors:  Satoshi Ikeda; Kazuhiko Takabe; Masaharu Inagaki; Keiko Suzuki
Journal:  Pathol Int       Date:  2010-10-06       Impact factor: 2.534

Review 6.  Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.

Authors:  Marta Batus; Mary Jo Fidler; Philip D Bonomi
Journal:  Expert Rev Anticancer Ther       Date:  2010-10       Impact factor: 4.512

7.  sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients.

Authors:  Engin Ulukaya; Ceyda Acilan; Meryem Yilmaz; Arzu Yilmaztepe-Oral; Ferda Ari; Berrin Zik; Ahmet Ursavas; Asuman H Tokullugil
Journal:  Cell Biochem Funct       Date:  2010-10       Impact factor: 3.685

8.  Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin.

Authors:  Dan Zhao; Dongkui Xu; Xuemei Zhang; Li Wang; Wen Tan; Yongli Guo; Dianke Yu; Hui Li; Ping Zhao; Dongxin Lin
Journal:  Gastroenterology       Date:  2009-05       Impact factor: 22.682

9.  Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer.

Authors:  Daniele Campa; Shanbeh Zienolddiny; Valentina Maggini; Vidar Skaug; Aage Haugen; Federico Canzian
Journal:  Carcinogenesis       Date:  2003-11-06       Impact factor: 4.944

10.  Aspirin and risk for gastric cancer: a population-based case-control study in Sweden.

Authors:  K Akre; A M Ekström; L B Signorello; L E Hansson; O Nyrén
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

View more
  1 in total

Review 1.  COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis.

Authors:  Jiaxi Li; Xiaochen Lu; Xinwei Zou; Yufeng Jiang; Jie Yao; Hongtao Liu; Bin Ni; Haitao Ma
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.